We are live on ! Find out more
XRTX icon

XORTX Therapeutics
XRTX

4 hedge funds and large institutions have $161M invested in XORTX Therapeutics in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

14,209,845% more capital inflows, than outflows

Capital inflows: $40.8M | Capital outflows: $287

0% more funds holding

Funds holding: 4 → 4 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

0.08% less ownership

Funds ownership: 0.08% → 0% (-0.08%)

Holders
4
Holders Change
–
Holders Change %
0%
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
3
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale
Germany
+$40.8M
2
Osaic Holdings
Osaic Holdings
Arizona
+$15.1K
3
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$7.67K
4
Clearstead Advisors
Clearstead Advisors
Ohio
+$3.62K

Top Sellers

Rank Fund Capital Flow
1
Toronto Dominion Bank
Toronto Dominion Bank
Ontario, Canada
-$286
2
Bank of America
Bank of America
North Carolina
-$1

XRTX Hedge Fund Activity: Q4 2023 in Review

4 of the 6,877 institutional investors tracked by Wall St. Rank reported a position in XORTX Therapeutics (XRTX) for Q4 2023, worth a combined $161M — up 2,004,184% from $8.01K a quarter earlier.

Fund positioning in XRTX was balanced in Q4 2023: 1 fund opened new positions, 1 closed out, 3 added to existing stakes and 0 trimmed.

The largest buyer was DekaBank Deutsche Girozentrale, opening a new position worth an estimated $40.8M. The largest seller was Toronto Dominion Bank, exiting entirely with an estimated $286 sold.

  • 4 institutional investors held XORTX Therapeutics (XRTX) as of Q4 2023, unchanged from Q3 2023.
  • Funds reported $161M of XORTX Therapeutics stock for Q4 2023, up 2,004,184% quarter-over-quarter.
  • 1 fund opened new XORTX Therapeutics positions in Q4 2023 and 1 closed out, a net change of 0 holders.
  • The largest XORTX Therapeutics buyer in Q4 2023 was DekaBank Deutsche Girozentrale, an estimated $40.8M added.
  • The largest XORTX Therapeutics seller in Q4 2023 was Toronto Dominion Bank, an estimated $286 sold.

Based on aggregated 13F filings for Q4 2023.